Characterization of a monoclonal antibody with CD44 like reactivity

G Kremmidiotis1, G Russ, R Starr

  • 1Department of Clinical Immunology, Flinders Medical Centre, Flinders University of South Australia, Bedford Park.

Disease Markers
|January 1, 1991
PubMed

Insights

Monoclonal antibody QE7.3E8 initially appeared to target CD18 but showed distinct staining patterns. Further experiments confirmed QE7.3E8 reacts with the CD44 antigen, not CD18.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Monoclonal antibodies are crucial tools in immunology for identifying cell surface antigens.
  • QE7.3E8 is a monoclonal antibody with an observed immunoprecipitation pattern.
  • Initial characterization suggested QE7.3E8 might be a CD18 antibody.

Purpose of the Study:

  • To clarify the precise cell surface antigen recognized by the monoclonal antibody QE7.3E8.
  • To differentiate QE7.3E8 from known CD18 and CD11 antibodies.
  • To determine the expression profile and molecular interactions of the antigen targeted by QE7.3E8.

Main Methods:

  • Immunoprecipitation assays using B cell lines, monocytes, and T cell lines.
  • Tissue staining and distribution analysis.
  • Cross-immunoprecipitation experiments.
  • Sequential immunoprecipitation with QE7.3E8 and a known CD44 antibody (SBU 25-32).

Main Results:

  • QE7.3E8 precipitated different band patterns from B cells (90, 160 kd) and monocytes (90, 130, 146, 160 kd).
  • Tissue distribution of QE7.3E8 differed significantly from CD18 antibodies.
  • QE7.3E8 precipitated four bands from T cells lacking CD11b/CD11c alpha chains, inconsistent with CD18.
  • Cross-immunoprecipitation showed no association between QE7.3E8 and CD11a targets.
  • Sequential precipitation experiments indicated QE7.3E8 reacts with CD44, consistent with its known high molecular weight complexes.

Conclusions:

  • The monoclonal antibody QE7.3E8 does not recognize the CD18 antigen.
  • QE7.3E8 specifically targets the CD44 antigen.
  • The multiple bands observed in immunoprecipitation are likely due to CD44 complexes, not distinct molecules associated with CD18.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.